iCeutica collaborates with pharmaceutical partners to enhance generics and late stage new chemical entities. They also extend the life cycle of existing products through new formulations, combination therapies, and novel delivery methods, all with renewed patent protection and FDA exclusivity periods. Their pipeline focuses on addressing pain and inflammation, oncology, and respiratory disease. iCeutica offers a nano-sizing platform that simplifies the reformulation process for various drugs. In 2011, the company was acquired by Iroko Pharmaceuticals, with the terms of the deal undisclosed.